Atrion (Atrion) Cash And Cash Equivalents

: $3.6 Mil (As of Dec. 2023)

View and export this data going back to 1972. Start your Free Trial

Atrion's quarterly cash and cash equivalents increased from Jun. 2023 ($0.31 Mil) to Sep. 2023 ($0.66 Mil) and increased from Sep. 2023 ($0.66 Mil) to Dec. 2023 ($3.57 Mil).

Atrion's annual cash and cash equivalents declined from Dec. 2021 ($32.26 Mil) to Dec. 2022 ($4.73 Mil) and declined from Dec. 2022 ($4.73 Mil) to Dec. 2023 ($3.57 Mil).

Atrion Cash And Cash Equivalents Historical Data

The historical data trend for Atrion's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atrion Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

45.05

22.45

32.26

4.73

3.57

Atrion Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents																4.73	4.56	0.31	0.66	3.57

Atrion Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Atrion (NAS:ATRI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Atrion Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Atrion's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Atrion (Atrion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atrion Corp (NAS:ATRI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Allentown Parkway, Allen, TX, USA, 75002-4211

Website

https://www.atrioncorp.com

Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.

Executives

Preston G Athey	director	ONE ALLENTOWN PKWY, ALLEN TX 75002
David A Battat	officer: President & CEO	2700 HALKEY-ROBERTS PLACE NORTH, ST. PETERSBURG FL 33716-4103
Jeannette Bankes	director	ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Morgan Hugh J Jr	director
Ronald Nicholas Spaulding	director	ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Cindy Ferguson	officer: Officer/ CFO	ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffery Strickland	officer: Vice President & CFO
Emile A Battat	director, officer: Chairman	ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Maria Sainz	director	C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Stupp John P Jr	director	STUPP JOHN P JR, #18 ST. ANDREWS DR., ST LOUIS MO 63124
Roger F Stebbing	director
Ronald N Spaulding	director	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Richard O Jacobson	director	ONE ALLENTOWN PARKWAY, C/O ATRION, ALLEN TX 75002
Maley John H P	director	6 ROCK CREST LANE, SIGNAL MOUNTAIN TN 37377
Margaret Maxwell Zagel	director	C/O TELLABS OPERATIONS INC, 4951 INDIANA AVE, LISLE IL 60532